Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 6/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4704189 | 0.91 | DPP4 (0.40) | DPP4ALDH1A1HTTPOLBCYP3A4 | |
| SCHEMBL4702304 | 0.85 | DPP4 (0.43) | DPP4ALDH1A1POLBCYP3A4CYP2C19 | |
| SCHEMBL6227656 | 0.85 | DPP4 (0.43) | DPP4ALDH1A1POLBCYP3A4CYP2C19 | |
| SCHEMBL6227658 | 0.85 | DPP4 (0.43) | DPP4ALDH1A1POLBCYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL4758744 | 0.82 | DPP4 (0.39) | DPP4ALDH1A1POLBF10GAA | |
| SCHEMBL4706597 | 0.82 | DPP4 (0.42) | DPP4ALDH1A1POLBCYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL5936109 | 0.82 | DPP4 (0.38) | DPP4ALDH1A1POLBCYP3A4F10 | |
| SCHEMBL4706177 | 0.82 | F10 (0.40) | ALDH1A1POLBF10F2KLKB1 | |
| Hydrochloric Acid SCHEMBL4704064 | 0.81 | DPP4 (0.39) | DPP4POLBSMN1; SMN2F10F2 | |
| Hydrochloric Acid SCHEMBL4705563 | 0.81 | ALDH1A1 (0.40) | DPP4ALDH1A1HTTPOLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567489-B1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | GLAXO GROUP LIMITED (GB) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | TFPI, TFPI2, SERPINC1 | DPP4 383/4885ALDH1A1 3827/4885HTT 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.